XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS AND GOODWILL (Tables)
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of net-book value and estimated remaining life and finite lived intangible assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2025:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at March 31, 2025
Finite-lived intangible assets
Trade name10.6$104,000 $(36,965)$67,035 
Customer relationships5.84,000 (1,444)2,556 
Patents and licenses9.359,492 (14,116)45,376 
Acquired developed technology (1)6.2887,480 (433,574)453,906 
Total finite-lived intangible assets1,054,972 (486,099)568,873 
In-process research and developmentn/a420,000 — 420,000 
Total intangible assets$1,474,972 $(486,099)$988,873 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2024:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at December 31, 2024
Finite-lived intangible assets
Trade name10.8$104,000 $(35,153)$68,847 
Customer relationships6.04,000 (1,333)2,667 
Patents and licenses9.556,542 (12,963)43,579 
Acquired developed technology (1)6.4887,104 (412,504)474,600 
Total finite-lived intangible assets1,051,646 (461,953)589,693 
In-process research and developmentn/a420,000 — 420,000 
Total intangible assets$1,471,646 $(461,953)$1,009,693 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”).
Schedule of estimated future amortization expense, intangible assets
As of March 31, 2025, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2025 (remaining nine months)$72,490 
202695,607 
202795,607 
202895,607 
202989,484 
Thereafter120,078 
$568,873 
Schedule of carrying amount of goodwill
The change in the carrying amount of goodwill for the periods ended March 31, 2025 and December 31, 2024 is as follows:
(In thousands)
Balance, January 1, 2024
$2,367,120 
Resolution Bioscience acquisition adjustments225 
Effects of changes in foreign currency exchange rates (1)(669)
Balance, December 31, 2024
2,366,676 
Effects of changes in foreign currency exchange rates (1)435 
Balance March 31, 2025
$2,367,111 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra.